Mutation feature of C12orf75 in different tumors of TCGA and correlation of C12orf75 expression with immune infiltration level in BLCA, KIRP, and LIHC. The alteration frequency with mutation type (A) and mutation site (B) are displayed. (C) In BLCA, C12orf75 expression has a significant negative correlation with tumor purity, a significant positive correlation with infiltrating levels of CD8+ T cell, macrophage, neutrophil, and dendritic cell, and no relation with infiltrating levels of B cell and CD4+ T cell. (D) In KIRP, C12orf75 expression has no significant correlation with tumor purity, significant negative correlation with infiltrating levels of B cell and, CD8+ T cell, and no relation with infiltrating levels of CD4+ T cell, macrophage, neutrophil, and dendritic cell. (E) In LIHC, C12orf75 expression has no significant correlation with tumor purity and, significant positive correlation with infiltrating levels of B cell, CD8+ T cell, CD4+ T cell, macrophage, neutrophil, and dendritic cell. ACC, adrenocortical carcinoma; AML, acute myeloid leukemia; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; CRAC, colorectal cancer; DLBC, lymphoid neoplasm diffuse large B-cell lymphoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LGG, brain lower grade glioma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; MM, malignant melanoma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; PRCC, papillary renal cell carcinoma; SARC, Sarcoma; STAD, Stomach adenocarcinoma; TGCT, testicular germ cell tumors; THCA, thyroid carcinoma; THYM, thymoma; UC, uterine cancer; UCS, uterine carcinosarcoma; UVM, uveal melanoma. P-values were corrected using the Benjamini-Hochberg method. p < 0.05 is considered as significant.